Royce & Associates LP Acquires 238,158 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Royce & Associates LP raised its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 34.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 929,613 shares of the company’s stock after purchasing an additional 238,158 shares during the quarter. Royce & Associates LP owned 0.96% of ARS Pharmaceuticals worth $9,807,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of SPRY. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of ARS Pharmaceuticals by 4.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 80,641 shares of the company’s stock worth $851,000 after purchasing an additional 3,433 shares during the last quarter. Raymond James Financial Inc. bought a new stake in ARS Pharmaceuticals during the fourth quarter worth about $6,576,000. Aigen Investment Management LP bought a new stake in ARS Pharmaceuticals during the fourth quarter worth about $216,000. Charles Schwab Investment Management Inc. increased its holdings in shares of ARS Pharmaceuticals by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 427,477 shares of the company’s stock worth $4,510,000 after buying an additional 3,530 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of ARS Pharmaceuticals by 47.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 38,050 shares of the company’s stock valued at $401,000 after acquiring an additional 12,200 shares during the last quarter. 68.16% of the stock is currently owned by institutional investors.

Insider Activity

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $11.10, for a total value of $555,000.00. Following the transaction, the director now directly owns 210,346 shares of the company’s stock, valued at approximately $2,334,840.60. This trade represents a 19.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have sold 149,600 shares of company stock valued at $1,726,516. 40.10% of the stock is currently owned by insiders.

ARS Pharmaceuticals Stock Up 0.8 %

Shares of SPRY stock opened at $11.53 on Wednesday. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -22.61 and a beta of 1.03. ARS Pharmaceuticals, Inc. has a 12 month low of $7.55 and a 12 month high of $18.51. The stock has a 50-day moving average price of $11.98 and a 200 day moving average price of $13.04.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on SPRY shares. Raymond James raised their price target on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 14th. William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Scotiabank started coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 price target on the stock. Leerink Partners raised their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Finally, Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a research report on Monday, February 10th. They set an “outperform” rating and a $40.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $31.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.